Organon (OGN) Retained Earnings (2020 - 2026)
Organon (OGN) recorded quarterly Retained Earnings of -$539.0 million in Q1 2026, down 148.6% quarter-over-quarter from $1.1 billion in Q4 2025, and down 152.53% on a YoY basis from $1.0 billion in Q1 2025.
Organon (OGN) Retained Earnings (2020 - 2026) Analysis & Trends
Organon's Retained Earnings history runs 7 years deep, the most recent figure standing at -$539.0 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 152.53% year-over-year to -$539.0 million; the TTM figure through Mar 2026 stood at -$539.0 million (down 152.53% YoY), while the FY2025 annual figure was $1.1 billion, up 270.88% from the prior year.
- Retained Earnings was -$539.0 million for Q1 2026 at Organon, down from $1.1 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.3 billion in Q3 2025 to a low of -$649.0 million in Q4 2024.
- Historically, Retained Earnings has averaged -$28.9 million across 5 years, with a median of -$529.0 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings slumped 3468.75% in 2024, then soared 330.82% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$564.0 million in 2022, then soared by 178.55% to $443.0 million in 2023, then sank by 246.5% to -$649.0 million in 2024, then soared by 270.88% to $1.1 billion in 2025, then sank by 148.6% to -$539.0 million in 2026.
- The last three Retained Earnings figures came in at -$539.0 million (Q1 2026), $1.1 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | 1.90 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | 29.51 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | -14.83 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | -17.87 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | -1.37 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | -539.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -539.00 Mn |
| Dec 31, 2025 | 1.11 Bn |
| Sep 30, 2025 | 1.32 Bn |
| Jun 30, 2025 | 1.16 Bn |
| Mar 31, 2025 | 1.03 Bn |
| Dec 31, 2024 | -649.00 Mn |
| Sep 30, 2024 | -571.00 Mn |
| Jun 30, 2024 | -612.00 Mn |
| Mar 31, 2024 | -577.00 Mn |
| Dec 31, 2023 | 443.00 Mn |
| Sep 30, 2023 | -16.00 Mn |
| Jun 30, 2023 | -25.00 Mn |
| Mar 31, 2023 | -534.00 Mn |
| Dec 31, 2022 | -564.00 Mn |
| Sep 30, 2022 | -383.00 Mn |
| Jun 30, 2022 | -551.00 Mn |
| Mar 31, 2022 | -529.00 Mn |
| Dec 31, 2021 | -513.00 Mn |
| Sep 30, 2021 | -493.00 Mn |
| Jun 30, 2021 | 81.00 Mn |